三個皮匠報告
政策庫
new
付費
搜索

耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例-行業數據

耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例
◆ 鏡下血尿：在中國人群中，與基線相比，耐賦康組2年內無鏡下血尿的患者比例從26.9%顯著改善至57.7%,而安慰劑組幾乎無變化。與安慰劑組相比，耐賦康治療組 24 個月時無鏡下血尿的患者比例明顯更高。
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?481KB 圖片尺寸：3403*1339
同報告圖片
 / 65
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第1頁
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
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第2頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第3頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第4頁
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
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第5頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第6頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第7頁
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
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第8頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第9頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第10頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第11頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第12頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第13頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第14頁
fCDmlYjlupTpg6jkvY0gfCDnu4bog57nsbvlnosgfCDnu4bog57lm6DlrZAgfAp8IC0tLSB8IC0tLSB8IC0tLSB8Cnwg5pWI5bqUL+iusOW/hiBU57uG6IOeIHwgVGgxIHwgSUwtMTIgfAp8IOaViOW6lC/orrDlv4YgQue7huiDniB8IFRoMiB8IElMLTEwIHwKfCBC57uG6IOeIHwgVEdGLc6yIHwgVHJlZyB8CgrotYTmlpnmnaXmupDvvJrjgIrljLvlrablhY3nlqvlrabvvIjnrKw554mI77yJ77yIMjAyMu+8ieOAi++8jOmVv+WfjuivgeWIuOS6p+S4mumHkeiejeeglOeptumZog==
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第15頁
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
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第16頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第17頁
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
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第18頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第19頁
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
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第20頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第21頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第22頁
fCBJZ0EgfCBDMyB8CnwgLS0tIHwgLS0tIHwKfCDnu7/oibLojaflhYkgfCDpu5HoibLog4zmma8gfAoK6LWE5paZ5p2l5rqQ77ya44CKSWdB6IK+55eF77yI56ysMueJiO+8ie+8iDIwMjLvvInjgIvvvIzplb/ln47or4HliLjkuqfkuJrph5Hono3noJTnqbbpmaI=
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第23頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第24頁
fCDlubTpvoTmrrUgICB8IEVTUkTmrbvkuqHnjofvvIjmr4/ljYPkurrlubTvvIkgfAp8LS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCAxOC00NOWygSAgfCAxMS44ICAgICAgICAgICAgICAgICAgICAgfAp8IDQ1LTY05bKBICB8IDMxLjU3ICAgICAgICAgICAgICAgICAgICB8CnwgNjXlsoHlj4rku6XkuIogfCA5MS42OSAgICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5Lit5Zu96IK+6ISP55a+55eF5pWw5o2u572R57uc77yM6ZW/5Z+O6K+B5Yi45Lqn5Lia6YeR6J6N56CU56m26Zmi5rOo77ya5pWw5o2u57uf6K6h5LqOMjAxNeW5tA==
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第25頁
fCDlj4LmlbAgfCDmj4/ov7AgfAp8IC0tLSB8IC0tLSB8CnwgQSB8IOiCvuWwj+eQg+iKguauteaAp+ehrOWMliAoUEFTTSDmn5PoibIgeDQwMCkgfAp8IEIgfCDogr7lsI/nkIPoioLmrrXmgKfnoazljJblj4rnkIPlm4rnspjov54gfAoK6LWE5paZ5p2l5rqQ77ya44CKSWdB6IK+55eF77yI56ysMueJiO+8ie+8iDIwMjLvvInjgIvvvIzplb/ln47or4HliLjkuqfkuJrph5Hono3noJTnqbbpmaLjgII=
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第26頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第27頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第28頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第29頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第30頁
fCDnlr7nl4XlkI3np7AgICAgICAgfCDnlr7nl4XotJ/mi4XnjofvvIhEQUxZcy/ljYHkuIfkurrvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCDlv4PooYDnrqHnlr7nl4UgICAgIHwgNjQ2MyAgICAgICAgICAgICAgICAgICAgIHwKfCDogr/nmKQgICAgICAgICAgIHwgNDc0NyAgICAgICAgICAgICAgICAgICAgIHwKfCDmhaLmgKfpmLvloZ7mgKfogrrnl4UgfCAxNDA0ICAgICAgICAgICAgICAgICAgICAgfAp8IOezluWwv+eXhSAgICAgICAgIHwgNjk2ICAgICAgICAgICAgICAgICAgICAgIHwKfCDpmL/lsJTlhbnmtbfpu5jnl4cgICB8IDQyMCAgICAgICAgICAgICAgICAgICAgICB8Cnwg5oWi5oCn6IK+55eFICAgICAgIHwgNDEwICAgICAgICAgICAgICAgICAgICAgIHwKfCDmhaLmgKfogp3nl4UgICAgICAgfCAzMDUgICAgICAgICAgICAgICAgICAgICAgfAp8IOeyvuelnuWIhuijgiAgICAgICB8IDI1MSAgICAgICAgICAgICAgICAgICAgICB8Cnwg5raI5YyW6YGT55a+55eFICAgICB8IDE2MyAgICAgICAgICAgICAgICAgICAgICB8Cnwg55S156a75Y+K55S156OB55a+55eFIHwgMTE4ICAgICAgICAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muiJvuaYhueOru+8jOWFqOeQg+eWvueXhei0n+aLhUlITUXmlbDmja7lupPvvIzplb/ln47or4HliLjkuqfkuJrph5Hono3noJTnqbbpmaLms6jjgILmlbDmja7nu5/orqHkuo4yMDE55bm044CC
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第31頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第32頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第33頁
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
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第34頁
fCDml7bpl7TngrkgfCDkuK3lm70qIChuPTI2KSB8IOWFqOeQgyogKG49MjEpIHwg5Lit5Zu9KiAobj0yNikgfCDlhajnkIMqIChuPTIxKSB8CnwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwKfCDln7rnur8gfCAyNi45JSAgICAgICAgfCAxNC4zJSAgICAgICAgfCAzMy41JSAgICAgICAgfCAzMi4yJSAgICAgICAgfAp8IOinguWvn+maj+iuv+acn+mXtCB8IDU3LjclICAgICAgICB8IDE0LjMlICAgICAgICB8IDU5LjUlICAgICAgICB8IDM4LjglICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrogr7ljLvnur/lhazkvJflj7fvvIzplb/ln47or4HliLjkuqfkuJrph5Hono3noJTnqbbpmaI=
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第35頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第36頁
fCDnlr7nl4XnsbvlnosgICB8IOeZvuWIhuavlCB8CnwtLS0tLS0tLS0tLS18LS0tLS0tLS18Cnwg57OW5bC/55eF6IK+55eFIHwgMjcuMCUgIHwKfCDpq5jooYDljovogr7nl4UgfCAyMC44JSAgfAp8IOail+mYu+aAp+iCvueXhSB8IDE1LjYlICB8Cnwg6IK+5bCP55CD6IK+54KOIHwgMTUuMSUgIHwKfCDlhbbku5bnl4Xlm6AgICB8IDIxLjUlICB8CgrotYTmlpnmnaXmupDvvJrkuK3lm73ogr7ohI/nlr7nl4XmlbDmja7nvZHnu5zvvIzplb/ln47or4HliLjkuqfkuJrph5Hono3noJTnqbbpmaLms6jvvJrmlbDmja7nu5/orqHkuo4yMDE15bm0
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第37頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第38頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第39頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第40頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第41頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第42頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第43頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第44頁
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
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第45頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第46頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第47頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第48頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第49頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第50頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第51頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第52頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第53頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第54頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第55頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第56頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第57頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第58頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第59頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第60頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第61頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第62頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第63頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第64頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第65頁
耐賦康臨床3期試驗中國亞組和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第66頁
所屬報告： 醫藥行業IgA腎病專題：潛在需求龐大耐賦康放量確定性高-240918（71頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站